CREDIT SUISSE AG/ - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 150 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2014. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2018$655,000
-15.0%
281,080
+3.6%
0.00%0.0%
Q4 2017$771,000
+15.2%
271,306
+16.1%
0.00%0.0%
Q3 2017$669,000
+57.4%
233,635
+35.8%
0.00%
Q2 2017$425,000
-51.5%
172,033
-29.2%
0.00%
-100.0%
Q1 2017$877,000
+144.3%
243,073
+139.8%
0.00%
Q4 2016$359,000
-61.7%
101,384
-56.4%
0.00%
-100.0%
Q3 2016$938,000
-13.8%
232,428
-6.3%
0.00%0.0%
Q2 2016$1,088,000
-41.5%
247,957
-49.6%
0.00%
-50.0%
Q1 2016$1,860,000
-47.1%
491,801
+119.2%
0.00%
-50.0%
Q4 2015$3,519,000
+98.1%
224,395
+33.2%
0.00%
+100.0%
Q3 2015$1,776,000
-80.7%
168,488
-53.9%
0.00%
-77.8%
Q2 2015$9,215,000
+15.5%
365,408
+27.7%
0.01%
+12.5%
Q1 2015$7,977,000
+56.4%
286,233
+2.5%
0.01%
+60.0%
Q4 2014$5,099,000
+88.4%
279,356
+33.8%
0.01%
+150.0%
Q3 2014$2,707,000
+10.8%
208,852
+39.4%
0.00%0.0%
Q2 2014$2,444,000
-44.0%
149,795
-39.4%
0.00%
-50.0%
Q1 2014$4,366,000
+26.6%
247,108
+73.5%
0.00%
+33.3%
Q4 2013$3,449,000
+63.3%
142,453
+138.9%
0.00%
+50.0%
Q3 2013$2,112,000
+55.6%
59,631
-31.5%
0.00%
+100.0%
Q2 2013$1,357,000
+0.1%
87,014
-25.7%
0.00%0.0%
Q1 2013$1,356,000117,1770.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2014
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,006$3,457,000100.00%
Meditor Group Ltd 6,312,700$3,179,0000.62%
TSP Capital Management Group, LLC 1,328,207$669,0000.34%
GREAT POINT PARTNERS LLC 804,483$405,0000.06%
Telemetry Investments, L.L.C. 252,300$127,0000.05%
Centiva Capital, LP 187,749$95,0000.02%
Benchmark Capital Advisors 54,400$27,0000.02%
GSA CAPITAL PARTNERS LLP 639,800$322,0000.02%
BOENNING & SCATTERGOOD, INC. 79,400$40,0000.01%
LMR Partners LLP 408,846$206,0000.01%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders